Board of Directors
A majority of the members of our board of directors, including Directors Savage and Brownlie are independent of us and our management under applicable standards of the Nasdaq Capital Market and the Nasdaq OMX Stockholm Exchange
Alan Dunton became a member of our Board on January 5, 2012 and serves as Non-Executive Chairman. Dr. Dunton is the Founder of Danerius, LLC, a consulting company that advises pharmaceutical and biotechnology companies on issues related to drug development, licensing and regulatory matters. He is currently a Director at Targacept, Inc., Palatin Technologies and Oragenics, Inc. From 2007 to 2009 Dr. Dunton served as President and CEO of Panacos Pharmaceuticals Inc., a NASDAQ-listed biotechnology company. From 2003 to 2005 Dr. Dunton was President, CEO and a Director of Metaphore Pharmaceuticals, Inc., and served as Chairman of ActivBiotics, Inc. in 2006 after the two companies merged. In 2002 he was President and COO of Emisphere Technologies, Inc. From 1994 to 2002 Dr. Dunton was a senior executive in various capacities within the Pharmaceuticals Group of Johnson & Johnson, including President of The Janssen Research Foundation where he was responsible for the development and regulatory activities for such blockbuster drugs as Levaquin®, Topamax® and Risperdal® line extensions. Earlier in his career he held clinical research and clinical pharmacology positions at Syntex Corporation, Ciba-Geigy Corporation, Hoffmann La Roche Inc. and Revlon Health Care Group.
Robert G. Savage has been a member of our Board since December 2004, and served as Chairman through December 2011. Mr. Savage has been a top pharmaceutical executive for more than 25 years. He held the position of Worldwide Chairman of the Pharmaceuticals Group at Johnson & Johnson with annual net sales of over $13 billion and was both a Company Officer and a member of the Executive Committee. He also served Johnson & Johnson in the capacity of a Company Group Chairman and President of Ortho-McNeil Pharmaceuticals. Most recently, Mr. Savage was President for the General Therapeutics and Inflammation Business for Pharmacia Corporation where he was President of the Worldwide Inflammation Group. He has held multiple positions leading marketing, business development and strategic planning at Hoffmann-La Roche and Sterling Drug. Mr. Savage is a director of The Medicines Company, a specialty pharmaceutical company. Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.
Keith L. Brownlie joined our board of directors in April 2011. Mr. Brownlie spent his entire career with the accounting firm of Ernst & Young LLP, retiring from the New York/New Jersey offices in 2010 after 36 years with the firm. At Ernst & Young, he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York Metro Area and New Jersey. Mr. Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant. Mr. Brownlie co-founded the New Jersey Entrepreneur of the Year Program and was co-chair of the BIONJ/PABIO Annual Symposium.